Search Results - "Kamal, Enas M"

Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant? by El-Khayat, Hesham, Yakoot, Mostafa, El-Shabrawi, Mortada, Fouad, Yasser, Attia, Dina, Kamal, Enas M.

“…BACKGROUND:Reactivation of hepatitis B virus (HBV) infection in patients treated for chronic hepatitis C (HCV) with direct-acting antiviral agents has emerged…”
Get full text

Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3‐6 years of age by Kamal, Enas M., El‐Shabrawi, Mortada, El‐Khayat, Hisham, Yakoot, Mostafa, Sameh, Yehia, Fouad, Yasser, Attia, Dina

“…Background & Aims Treatment of children aged 3‐6 genotype 4 is still limited by the interferon side effects. We aimed in this study to evaluate the…”
Get full text

Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients by El-Khayat, Hesham, Kamal, Enas M, Yakoot, Mostafa, Gawad, Manal A, Kamal, Naglaa, El Shabrawi, Mortada, Sameh, Yehia, Haseeb, Alaa, Fouad, Yasser, Attia, Dina

“…BACKGROUNDThe sustained virological response (SVR) rate for the 12-week sofosbuvir (SOF)/ledipasvir (LVD) treatment of adolescent genotype-4 patients is high…”
Get full text

Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma by Fouad, Yasser M., Mohamed, Hala I., kamal, Enas M., Rasek, Mohamed A.

“…Background: Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide. It has been widely established that the early detection of HCC…”
Get full text

Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors' failure: efficacy and safety of different regimens by El-Khayat, Hisham, Kamal, Enas M., Mahmoud, Hani, Gomaa, Ahmed, Ebeid, Bassel, Sameh, Yehia, Hasseb, Alaa, El Raziky, Maissa, El Serafy, Magdy, Doss, Wahid, Esmat, Gamal, Fouad, Yasser, Attia, Dina

“…BACKGROUND:Nonstructural protein 5A (NS5A) is an important regimen for the treatment of chronic hepatitis C virus (HCV) genotype-4 infected patients…”
Get full text

Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection by Yakoot, Mostafa, El-Shabrawi, Mortada H, AbdElgawad, Manal M, Mahfouz, Aml A, Khalil, Ahmed F, Kamal, Naglaa M, Helmy, Sherine, Abdo, Alaa M, Kamal, Enas M, El-Khayat, Hisham R

“…Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected…”
Get full text

Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy by El-Shabrawi, Mortada HF, Sherief, Laila M, Yakoot, Mostafa, Kamal, Naglaa M, Almalky, Mohamed A, AbdElgawad, Manal M, Mahfouz, Aml A, Helmy, Sherine, Kamal, Enas M, Attia, Dina, El-Khayat, Hisham R

“…BACKGROUNDChildhood cancer survivors are potentially at a higher risk of infection with hepatitis C virus (HCV). The effects of all-oral direct-acting…”
Get full text

Expression of Proteinase-activated Receptor-2 in the Esophageal Mucosa of Gastroesophageal Reflux Disease Patients: A Histomorphologic and Immunohistochemical Study by Abd El-Rehim, Dalia M, Fath El-Bab, Hanaa K, Kamal, Enas M

“…Data are limited regarding the role of proteinase-activated receptor-2 (PAR-2) in the esophageal mucosa in gastroesophageal reflux disease (GERD) patients. Our…”
Get full text